Clinical trial
Avastin and Tarceva for Upper Gastrointestinal Cancers
NCT00350753 · Rigshospitalet, Denmark, Other · Completed
Key facts
| NCT number | NCT00350753 |
|---|---|
| Title | Avastin and Tarceva for Upper Gastrointestinal Cancers |
| Official title | A Phase II Study of Erlotinib and Bevacizumab in Patients With Advanced Upper Gastrointestinal Carcinomas, Refractory or Intolerable to Standard Systemic Therapy |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Collaborators | Aarhus University Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cholangiocarcinoma, Gallbladder Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib and bevacizumab |
| Enrollment | 126 |
| Start date | Jun 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jul 11, 2006 |
| Last update posted | Jul 15, 2009 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: